Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing TSA
Not Applicable
Completed
- Conditions
- Osteoarthritis: Shoulder
- Interventions
- Procedure: Interscalene brachial plexus blockProcedure: bupivacaine extended-release liposome injection
- Registration Number
- NCT02695758
- Lead Sponsor
- Rothman Institute Orthopaedics
- Brief Summary
A non-blinded randomized controlled trial, in which participants undergoing primary reverse or total shoulder arthroplasty are randomly assigned to one of two treatment groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 156
Inclusion Criteria
- All individuals undergoing primary reverse and total shoulder arthroplasty by the shoulder service at Methodist Hospital or Rothman Specialty Hospital.
Exclusion Criteria
- Psychiatric illness as defined by co-morbid diagnosis of bipolar disorder or schizophrenia
- Revision arthroplasty, arthroplasty for fracture
- Unable/unwilling to consent for enrollment
- Unable to complete postoperative pain survey
- Known adverse drug reaction or allergy to the medications used
- Chronic pain syndromes (including reflex sympathetic dystrophy, fibromyalgia, chronic diffuse musculoskeletal pain)
- Patients taking long acting narcotic pain medications (including extended release narcotic pain medications and methadone).
- Patients under the age of 18 years
- Patients with history of hepatic disease
- Pregnant women or women who are breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description interscalene brachial plexus block Interscalene brachial plexus block Direct interscalene nerve block injection via brachial plexus Bupivacaine extended-release liposome injection bupivacaine extended-release liposome injection Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
- Primary Outcome Measures
Name Time Method Morphine and Morphine Equivalent consumption 24 hours following surgery
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bupivacaine liposome's analgesic effect in shoulder arthroplasty?
How does interscalene nerve block compare to local intraoperative analgesia in TSA postoperative pain management?
Are there specific biomarkers that predict optimal response to extended-release bupivacaine in shoulder surgery?
What are the long-term adverse event profiles of interscalene nerve blocks versus local analgesic injections in TSA patients?
What alternative analgesic compounds or combination therapies are being evaluated for shoulder arthroplasty pain management?